Loading...

Cytocom, Inc.

CBLI•NASDAQ
Healthcare
Biotechnology
$3.17
$-0.25(-7.31%)

Cytocom, Inc. (CBLI) Stock Overview

Explore Cytocom, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.7/100

Key Financials

Market Cap226.4M
P/E Ratio-16.38
EPS (TTM)N/A
ROE-1.60%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$3.45

CBLI Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cytocom, Inc. (CBLI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $3.45.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -16.38 and a market capitalization of 226.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
N/A
6-Month Change
N/A
Year-to-Date (YTD) Change
N/A
1-Year Change
252.18%
3-Year Change
56.93%
5-Year Change
-2.46%
All-Time (Max) Change
-97.01%

Contact Information

http://www.cytocom.com
17168496810
73 High St, Buffalo, NY

Company Facts

18 Employees
IPO DateJul 21, 2006
CountryUS

Frequently Asked Questions

;